Phreesia, Inc.
NYSE:PHR · New York Stock Exchange
+$0.08 today
Vol 0.82M · Avg 1.97M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:PHR · Revenue to Net Income
Key Ratios
Analysis
$495.6M of revenue converted into $9.2M of net income for the selected period. Gross margin is 65.9% and net margin is 1.8%, showing how much revenue survives after costs and taxes. EPS is $0.15, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $480.6M +14.5% | $419.8M +17.8% | $356.3M +26.8% | $280.9M +31.7% | $213.2M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $154.1M +14.2% | $134.9M +8.8% | $124.0M +13.5% | $109.3M +34.3% | $81.4M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $326.5M +14.6% | $284.9M +22.6% | $232.3M +35.3% | $171.6M +30.2% | $131.8M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 67.9% +0.1pp | 67.9% +2.7pp | 65.2% +4.1pp | 61.1% -0.7pp | 61.8% | 45.5% | 9.8% | 28.9% |
| Research & Development | $121.5M +3.5% | $117.4M +4.5% | $112.3M +23.1% | $91.2M +74.6% | $52.3M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $180.1M -8.9% | $197.7M -12.9% | $226.9M -2.0% | $231.6M +32.3% | $175.1M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $333.1M -2.9% | $343.0M -7.0% | $368.8M +5.9% | $348.2M +40.0% | $248.7M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $31.5M +12.8% | $27.9M -8.7% | $30.5M +6.2% | $28.8M +17.3% | $24.5M | $1.2B | $374.2M | $1.2B |
| EBITDA | $29.5M +215.2% | -$25.6M +75.2% | -$102.9M +29.2% | -$145.5M -57.6% | -$92.3M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 6.1% +12.2pp | -6.1% +22.8pp | -28.9% +22.9pp | -51.8% -8.5pp | -43.3% | 10.0% | 5.6% | 46.3% |
| Operating Income | -$6.6M +88.6% | -$58.1M +57.4% | -$136.5M +22.7% | -$176.6M -51.1% | -$116.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -1.4% +12.5pp | -13.8% +24.5pp | -38.3% +24.5pp | -62.9% -8.1pp | -54.8% | 18.7% | 16.6% | 24.1% |
| Interest Income | $2.2M -18.8% | $2.7M -34.1% | $4.1M +64.2% | $2.5M +3032.9% | $79.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $7.0M +196.3% | $2.3M +26.6% | $1.9M +31.4% | $1.4M +21.3% | $1.2M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$2.3M -201.8% | $2.3M +101.1% | $1.1M +27.9% | $889.0K +176.5% | -$1.2M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$8.9M +84.0% | -$55.8M +58.8% | -$135.3M +23.0% | -$175.7M -48.9% | -$118.0M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -1.9% +11.4pp | -13.3% +24.7pp | -38.0% +24.5pp | -62.5% -7.2pp | -55.3% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | -$11.2M -514.1% | $2.7M +76.0% | $1.5M +219.5% | $483.0K +165.4% | $182.0K | $666.8M | $1.3B | -$1.6B |
| Net Income | $2.3M +103.9% | -$58.5M +57.2% | -$136.9M +22.3% | -$176.1M -49.1% | -$118.2M | $5.0B | $4.9B | $4.8B |
| Net Margin | 0.5% +14.4pp | -13.9% +24.5pp | -38.4% +24.3pp | -62.7% -7.3pp | -55.4% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $0 +103.8% | -$1 +59.4% | -$3 +25.3% | -$3 -41.8% | -$2 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $0 +103.7% | -$1 +59.4% | -$3 +25.3% | -$3 -41.8% | -$2 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $59.7M +3.7% | $57.6M +5.6% | $54.6M +4.0% | $52.4M +5.1% | $49.9M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $61.5M +6.8% | $57.6M +5.6% | $54.6M +4.0% | $52.4M +5.1% | $49.9M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.50B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
NovoCure Limited
NASDAQ:NVCR
$1.70B
Teladoc Health, Inc.
NYSE:TDOC
$1.41B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.27B
Schrödinger, Inc.
NASDAQ:SDGR
$1.16B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.12B
Omada Health
NASDAQ:OMDA
$1.04B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$920.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PHR generate?
Phreesia, Inc. (PHR) reported $480.59M of revenue in fiscal 2026.
Is PHR profitable?
Phreesia, Inc. (PHR) reported $2.31M of net income, with a net margin of 0.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.